Clarivate (CLVT) Q3 2026 Earnings Call Transcript

Clarivate reported Q3 continuing-operations revenue of $481.6 million, down 9.2% year over year largely due to disposals, while organic revenue grew 0.4%; adjusted diluted EPS rose $0.03 to $0.21 and adjusted EBITDA margin was 45.3%. The company set FY 2026 revenue guidance at $1.965 billion–$1.985 billion and adjusted EBITDA at $865 million–$885 million, and expects 2027 free cash flow growth of 10%–15%. A $62.2 million non-cash goodwill impairment contributed to an $80.8 million net loss including discontinued operations; management also cited progress in recurring growth, AI product pipelines and debt reduction.

Analysis

The key debate is whether Clarivate’s improving leading indicators represent durable demand or mostly price realization and cost control. Pricing can lift ACV before it lifts revenue, but if renewal retention and new subscription volumes do not strengthen, the promised acceleration will stall once price increases lap. The gap between positive ACV and weak IP organic revenue is therefore a near-term conversion test, not yet proof of a growth inflection.

The Q4 setup is asymmetric: management expects recurring growth above 2% and full-year adjusted EBITDA growth to arrive in Q4, so any miss could undermine confidence in both execution and the 2027 outlook. Watch renewal rates, net new sales, and recurring revenue—not AI call volumes or pipeline counts—as evidence of monetization. IPOne and Web of Science Research Intelligence could deepen workflow lock-in, but early-adopter activity and pipeline are not booked revenue; broad AI tools also raise the risk that customers resist premium pricing for research and IP analytics. RELX and Wolters Kluwer are relevant benchmarks for defensible data and workflow monetization, though not direct proxies for every Clarivate product.

Portfolio simplification and debt repurchases reduce complexity and refinancing exposure, but the business is now more concentrated in two franchises. Cash conversion deserves scrutiny: year-to-date operating cash flow fell despite adjusted earnings progress, while FX can pressure costs even when reported revenue is relatively insulated. Over 6–18 months, the thesis depends on volume-led growth, retention and cash conversion replacing price and cost actions. Falsifiers: Q4 recurring growth misses 2%, ACV fails to approach the 2% exit target, or 2027 free-cash-flow growth is not supported by improving operating cash flow.

Key Decisions for Investors

• Do not chase the reported inflection before Q4 confirmation. Treat CLVT as a catalyst watch: consider a measured long only after recurring growth exceeds 2% and management shows that retention or new subscription sales—not pricing alone—are contributing; reduce or avoid exposure if either condition fails.
• For the next 1–3 months, track IP ACV-to-revenue conversion, renewal/retention trends, and cash conversion against adjusted EBITDA. These are more decision-useful than AI API usage, institutional wins, or unconverted pipeline.
• Credit watch: debt repurchases should help near-term maturity risk, but verify the remaining 2028/2029 balances, buyback prices, and liquidity in filings before expressing a bond view. Prefer the credit thesis over an equity long only if leverage falls while free cash flow holds up.
• AI is an upside option, not yet a standalone earnings catalyst. Reassess when IPOne early-adopter usage converts into paid contracts, recurring ACV, or demonstrably better retention; otherwise, treat development-partner counts and pipeline as unproven.